Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6891504 | 1.00 | TDP1 (0.35) | TDP1TSHRGAA | |
| SCHEMBL9792836 | 0.84 | — | — | |
| SCHEMBL5823199 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL28583405 | 0.78 | — | — | |
| SCHEMBL992741 | 0.77 | TDP1 (0.33) | TDP1TSHR | |
| SCHEMBL4745787 | 0.75 | TSHR (0.31) | TSHR | |
| SCHEMBL2455808 | 0.75 | TDP1 (0.40) | TDP1TSHR | |
| SCHEMBL1328556 | 0.74 | TDP1 (0.31) | TDP1TSHR | |
| SCHEMBL1402719 | 0.74 | TDP1 (0.31) | TDP1TSHR | |
| SCHEMBL27864231 | 0.72 | TSHR (0.50) | TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541600-B2 | 11-aza, 11-thia and 11-oxa sterol compounds and compositions | Harbor Therapeutics, Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | BIOVIE INC. | 2012-02-16 | — | — | US | disclosed |
| US-7511125-B2 | Pyrimidine derivatives for labeled binding partners | CARLSBAD (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1223941-B1 | THERAPEUTIC TREATMENTS FOR BLOOD CELL DEFICIENCIES USING SREROIDS | HOLLIS EDEN PHARMACEUTICALS (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20050020826-A1 | Pyrimidine derivatives for labeled binding partners | LIN KUEI-YING (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1027364-B1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040220114-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040220161-A1 | Pharmaceutical compositions and treatment methods-6 | BIOVIE INC. | 2004-11-04 | — | — | US | disclosed |
| US-6800743-B2 | FOR USE AS LABELS IN DIAGNOSTIC ASSAYS AND IN ENHANCING BINDING TO COMPLEMENTARY BASES | ISIS PHARMACEUTICALS, INC. | 2004-10-05 | — | — | US | disclosed |
| US-20040116359-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1027364-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999024452-A9 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 1999-08-12 | — | — | WO | disclosed |
| WO-1999024452-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| EP-0739351-A4 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS INC (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5763588-A | Pyrimidine derivatives for labeled binding partners | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0739351-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| EP-0719272-A1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| US-5502177-A | POLYCYCLIC STRUCTURE BOUND TO OLIGONUCLEOTIDE, FLUORESCENT LABEL, IMMUNOASSAY | GILEAD SCIENCES, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| WO-1995018820-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995007918-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220161-A1 | Pharmaceutical compositions and treatment methods-6 | HSD17B7, HSD3B1, NR5A1 | TDP1 2807/4885TSHR 2450/4885GAA 4311/4885 |
| US-20040220114-A1 | Pharmaceutical compositions and treatment methods | HSD17B1, HSD17B7, HSD17B3 | TDP1 2430/4885TSHR 2545/4885GAA 3857/4885 |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | CYP51A1, HSD11B1, HSD3B1 | TDP1 1701/4885TSHR 1488/4885GAA 4022/4885 |
| US-20050020826-A1 | Pyrimidine derivatives for labeled binding partners | RBBP4, DDB1, DPYD | TDP1 198/4885TSHR 2518/4885GAA 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.